KARASU, N. Et Al. 2021. Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy. MEDICAL ONCOLOGY , vol.38, no.10 .

KARASU, N., Akalin, H., GÖKÇE, N., YILDIRIM, A., DEMİR, M., Kulak, H., ... ÇELİK, S.(2021). Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy. MEDICAL ONCOLOGY , vol.38, no.10.

KARASU, NİLGÜN Et Al. "Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy," MEDICAL ONCOLOGY , vol.38, no.10, 2021

KARASU, NİLGÜN Et Al. "Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy." MEDICAL ONCOLOGY , vol.38, no.10, 2021

KARASU, N. Et Al. (2021) . "Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy." MEDICAL ONCOLOGY , vol.38, no.10.

@article{article, author={NİLGÜN KARASU Et Al. }, title={Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy}, journal={MEDICAL ONCOLOGY}, year=2021}